According to latest report the global anti-inflammatory drugs market size was USD 120.46 billion in 2023, calculated at USD 130.70 billion in 2024, and is expected to reach around USD 272.35 billion by 2033, expanding at a CAGR of 8.5% from 2024 to 2033. North America anti-inflammatory drugs market accounted for over 41.11% market share in 2023.
Get Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/8529
The growth of the anti-inflammatory drugs market is significantly driven by the main goals of pain control, improved function, and enhanced health-related quality of life in patients.
The anti-inflammatory drugs market is experiencing rapid growth driven by their ability to reduce inflammation, a process involving the suppression of substances in the body that trigger swelling, pain, and redness. These drugs, particularly non-steroidal anti-inflammatory drugs (NSAIDs), exert their therapeutic effects by inhibiting cyclooxygenase (COX), an enzyme responsible for producing prostaglandins (PGs) implicated in inflammation. While COX-1 generates PGs that protect the stomach and kidney, COX-2 induces PGs contributing to inflammation-related pain and swelling.
NSAIDs are widely used across various painful conditions, although their prescription requires caution due to potential serious adverse effects, even with short-term use. In primary care settings, paracetamol is preferred over NSAIDs unless otherwise indicated, with naproxen or ibuprofen recommended as first-line treatments at the lowest effective dose and duration possible. This market overview highlights the broad application and careful management of anti-inflammatory drugs in healthcare practices, emphasizing their significant role in therapeutic strategies worldwide.
Nonsteroidal anti-inflammatory drugs (NSAIDs) stand out as the most commonly prescribed medications for managing musculoskeletal pain. Their clinical utility in alleviating mild-to-moderate pain is pivotal, balancing efficacy with considerations for potential side effects. This balanced approach underscores the expanding demand for anti-inflammatory drugs, fueled by the increasing emphasis on enhancing patient outcomes through effective pain management strategies.
- In January 2023, Sun Pharma acquired Disperzyme and Phlogam brands to strengthen its anti-inflammatory portfolio
Key Takeaways
- North America has captured the highest market share.
- By drug class, the anti-inflammatory biologics segment held the largest share of the market.
- By treatment, the arthritis segment is expected to grow at a notable rate.
- By route of administration, the oral segment led the market in 2023.
- By distribution channel, the over-the-counter segment led the market in 2023.
Immediate Delivery Available, Get Full Access@ https://www.novaoneadvisor.com/report/checkout/8529
Why Are Anti-inflammatory Drugs Important?
Anti-inflammatory drugs are crucial for managing a wide range of medical conditions characterized by inflammation. Inflammation is the body’s natural response to injury or infection, but when it becomes chronic or excessive, it can lead to serious health problems. Anti-inflammatory drugs play a vital role in alleviating symptoms associated with inflammatory diseases such as arthritis, asthma, inflammatory bowel diseases (IBD), and others. They help reduce pain, swelling, and stiffness, improving the quality of life for patients. Additionally, these drugs are essential in controlling inflammatory processes that contribute to cardiovascular diseases, certain cancers, and neurodegenerative disorders. By targeting specific pathways involved in inflammation, these medications not only provide relief but also help prevent long-term complications associated with chronic inflammation. Thus, anti-inflammatory drugs are indispensable in both acute and chronic medical care, offering relief and therapeutic management for numerous inflammatory conditions.
Anti-inflammatory Drugs Industry News:
- In May 2023, AbbVie Inc received U.S. Food and Drug Administration (FDA) approval for RINVOQ (upadacitinib) for the treatment of adults with moderately to severely active Crohn’s disease. This product approval is expected to help the company to enhance its product offerings in anti-inflammatory drugs and drive revenue progression.
- In March 2022, Pfizer Inc acquired Arena Pharmaceuticals. This acquisition enables the company to develop and enhance its product portfolio in gastroenterology, dermatology, and cardiology. This strategic acquisition helped the company to complements its capabilities and expertise in inflammation and immunology division.
Anti-inflammatory Drugs Market Dynamics
Driver
Clinical Efficacy of Anti-inflammatory Drugs
The clinical efficacy of non-aspirin NSAIDs in acute pain management, comparable to starting doses of opioids but with a distinct ceiling dose effect, serves as a significant driver for the anti-inflammatory drugs market. Unlike opioids, which pose risks of addiction and overdose, NSAIDs provide analgesic relief without the ceiling effect for their anti-inflammatory properties. Studies in arthritis patients have highlighted the efficacy of non-aspirin NSAIDs such as diclofenac and celecoxib in reducing pain, joint swelling, morning stiffness, and improving mobility compared to acetaminophen. These findings underscore the growing preference for NSAIDs in clinical practice, contributing to the expanding market for anti-inflammatory medications aimed at enhancing patient outcomes and comfort in acute pain management scenarios.
Restraint
Risk of Adverse Effects
The widespread use of NSAIDs is tempered by their potential for serious adverse effects such as cardiovascular events, gastrointestinal complications, renal failure, and hypersensitivity reactions. Despite the relatively low individual risk for each patient, the cumulative use of NSAIDs across communities heightens the overall concern for adverse events. This necessitates careful evaluation of individual patient risk factors before prescribing NSAIDs, thereby posing a restraint on the growth of the anti-inflammatory drugs market. Healthcare providers must balance the therapeutic benefits of NSAIDs with their associated risks, ensuring patient safety and regulatory compliance in clinical practice.
Opportunity
Advancements in Targeted Drug Delivery
The development of novel disease-targeted drug delivery strategies promises enhanced therapeutic efficacy in treating and preventing inflammatory diseases. By focusing on specific molecular pathways and minimizing systemic side effects, these advancements offer substantial opportunities for growth in the anti-inflammatory drugs market. Progressive research efforts aimed at understanding molecular mechanisms underlying inflammation contribute to the development of innovative therapies that improve treatment outcomes and patient care, driving the expansion of the market for anti-inflammatory drugs.
- In March 2024, Avalo secured a novel anti-inflammatory drug through the AlmataBio buyout.
Immediate Delivery Available, Get Full Access@ https://www.novaoneadvisor.com/report/checkou
